Neoadjuvant Chemotherapy in Stage II Luminal B Breast Cancer
Rationale for Completing Neoadjuvant Chemotherapy
- The American College of Surgeons and the National Comprehensive Cancer Network recommend completing the full planned course of neoadjuvant chemotherapy before proceeding to surgery, as this maximizes the chance of achieving a pathologic complete response and improves treatment delivery compared to the adjuvant setting 1, 2
- Neoadjuvant chemotherapy achieves significantly higher completion rates (>95%) compared to adjuvant chemotherapy (66%), ensuring patients receive the full intended dose of therapy, according to the American Thoracic Society 3, 4
- More than 85% of neoadjuvant patients complete all intended therapy versus less than 60% in the adjuvant setting, as reported by the American College of Chest Physicians 3, 4
Optimal Duration and Timing
- At least 6 cycles of chemotherapy should be administered over 4-6 months before surgery to maximize the chance of pathologic complete response, as recommended by the European Society for Medical Oncology 1, 2
- The standard regimen for luminal B breast cancer is AC (doxorubicin/cyclophosphamide) for 4 cycles followed by weekly paclitaxel or docetaxel, according to the National Comprehensive Cancer Network 5
Monitoring During Treatment
- Clinical examination combined with ultrasound and mammography should be performed 6-9 weeks after starting treatment to assess response, as recommended by the European Society for Medical Oncology 2
- If progressive disease occurs during neoadjuvant therapy, consider switching treatment or proceeding to surgery earlier to prevent the patient from becoming inoperable, according to the American Society of Clinical Oncology 2
Tumor Localization Considerations
- Percutaneous placement of imaging-detectable clips into the breast should be performed before starting neoadjuvant therapy to mark the tumor site, as recommended by the National Comprehensive Cancer Network 6, 5
Common Pitfalls to Avoid
- Stopping chemotherapy early to proceed to surgery reduces the chance of pCR and may compromise long-term outcomes, as reported by the American Society of Clinical Oncology 1, 2
- The only exception is documented progressive disease where continuing chemotherapy would delay necessary surgery, according to the European Society for Medical Oncology 2
Ensure Adequate Axillary Staging
- For clinically negative axillary lymph nodes, perform axillary ultrasound before neoadjuvant treatment, as recommended by the National Comprehensive Cancer Network 6
- If nodes are suspicious on imaging, core biopsy or FNA should be performed before starting chemotherapy, according to the American College of Radiology 6
- Sentinel lymph node biopsy can be performed before or after neoadjuvant therapy, though prechemotherapy biopsy provides additional staging information, as reported by the Society of Surgical Oncology 6, 5